Tumor Board: How new data in cervical cancer effects second-line treatment options-Tumor Board: How new data in cervical cancer effects second-line treatment options

Video Transcription

Video Summary

The video is a team report on the topic of how new data in cervical cancer affects second-line treatment options. The video is hosted by Rithi Solani, the IGCS Education Committee Chair and Director of Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at UCLA in Los Angeles. The report is supported in part by CGen and aims to provide meaningful opportunities for industry colleagues to gain exposure to the gynecologic oncology community and educate them on current and future treatments.<br /><br />The video begins with housekeeping items and introduces the panelists, Dr. Nicoletta Colombo from the University of Milano Bicocca and Dr. Leslie Randall from Virginia Commonwealth University. The panelists discuss a case presentation and polling questions related to treatment recommendations. They also discuss the results of the KINO 826 study, which showed that the addition of pembrolizumab to standard chemotherapy provided a benefit in progression-free survival and overall survival in patients with recurrent or metastatic cervical cancer.<br /><br />The panelists also discuss the use of tisodamab vedotin, an antibody drug conjugate that targets tissue factor and has shown promising results in clinical trials. They present data on the response rates and safety profile of tisodamab vedotin in combination with pembrolizumab or carboplatin. They emphasize the importance of personalized treatment decisions based on individual patient characteristics and the need for further research to optimize treatment strategies.<br /><br />Overall, the video provides a summary of the latest data and treatment options in cervical cancer and highlights the importance of personalized and targeted approaches in improving patient outcomes.

Keywords

cervical cancer

second-line treatment options

Rithi Solani

KINO 826 study

pembrolizumab

tisodamab vedotin

personalized treatment decisions

patient outcomes